Get the Daily Brief
Latest Biotech News
Eli Lilly Acquires Verve Therapeutics in $1.3 Billion Gene Editing Deal
Eli Lilly announced its acquisition of Verve Therapeutics for up to $1.3 billion, integrating Verve's gene-editing technology targeting cardiovascular disease into its pipeline. Verve's lead...
Breakthrough Single-Cell Analysis Elucidates Systemic Sclerosis Heterogeneity
Researchers utilizing single-cell RNA sequencing and spatial transcriptomics disclosed immune cell subsets implicated in the clinical variability of systemic sclerosis. Specific monocyte and CD8+...
Novel Dual Immunotherapy Gains Global Approval in Liver Cancer First-Line Treatment
The University of Hong Kong developed a dual checkpoint inhibitor therapy combining nivolumab and ipilimumab for unresectable hepatocellular carcinoma, receiving authorization across multiple...
Calibr-Skaggs Starts Phase 1 Trial of Switchable CAR-T Therapy for Metastatic Breast Cancer
Calibr-Skaggs launched the first-in-human clinical study testing a modular 'switchable' CAR-T therapy platform designed to improve control and safety in solid tumor treatments. The Phase 1 trial...
Yale Scientists Advance Multiplexed Precision Human Gene Editing
Yale University researchers developed an enhanced multiplex genome editing technique, significantly increasing the number of accurate edits per cell while minimizing off-target mutations. This...
Rice University Unveils Quantum Materials Breakthrough via Chiral Photonic Crystal Cavities
Rice researchers, led by Junichiro Kono, engineered a novel photonic-crystal cavity integrating lightly doped indium antimonide to preferentially enhance vacuum fluctuations of circularly...
Stanford Identifies Key Yew Tree Enzymes to Boost Cancer Drug Biosynthesis
Stanford scientists discovered missing enzymes critical for the biosynthesis of taxol, a vital chemotherapy drug sourced from yew trees. Utilizing single-nucleus RNA sequencing on stressed yew...
Verve Therapeutics Acquisition: Lilly’s $1.3B Bet on Gene Editing
Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion, including milestone payments contingent on clinical progress. Verve’s lead gene-editing candidate, VERVE-102, targets...
Sarepta’s Duchenne Gene Therapy: Safety Concerns Mount
Sarepta Therapeutics faces heightened scrutiny following a second death due to acute liver failure associated with its gene therapy Elevidys, approved for Duchenne muscular dystrophy. Both...
AI and Drug Discovery: Insilico Medicine’s Pan-KRAS Inhibitors
Insilico Medicine has announced the discovery of novel pan-KRAS inhibitors through its AI-powered generative platform Chemistry42. Combining structure-based drug design and scaffold hopping, the...
Immunotherapy Advances in Pancreatic and Liver Cancer
Recent studies report remarkable immunotherapy responses in subsets of pancreatic cancer patients treated solely with immune checkpoint inhibitors, exhibiting unprecedented progression-free...
AI Innovations Fueling Biotech R&D and Diagnostics
Multiple AI-driven initiatives are reshaping biotech research and diagnostics. Xaira Therapeutics has released an expansive Perturb-seq dataset to accelerate virtual cell modeling and AI drug...
AI Labs Expand U.S. Presence Amid Drug Discovery Push
Isomorphic Labs, an Alphabet-backed AI drug discovery company, has hired its first U.S.-based chief medical officer and established an office in Cambridge to facilitate clinical advancement of...
FDA Launches New Priority Review Voucher Program
The U.S. Food and Drug Administration unveiled a pilot priority review voucher program aiming to accelerate drug review times from up to a year down to as little as one month for treatments...
Cancer Biomarker and Imaging Research Accelerates with AI
Researchers have unveiled new AI-driven computational tools transforming biomarker discovery and medical imaging analysis. The recently published moPepGen platform enhances detection of diverse...
Advances in Sustainable and Circular Bioeconomy Strategies
A policy report highlights pathways for sustainable and circular aquaculture development in Germany and Brazil, emphasizing the potent yet underutilized freshwater aquaculture sectors. Separately,...
Neonatal Care Innovations: Training and Automated Monitoring
New educational programs using simulation-based training improve neonatal endotracheal intubation skills among clinicians, enhancing patient safety in critical care units. Complementing this,...
Lilly's $1.3 Billion Verve Therapeutics Acquisition Shakes Cardiovascular Gene Editing
Eli Lilly agreed to acquire Verve Therapeutics for up to $1.3 billion, marking a strategic move to expand its cardiovascular gene editing portfolio. Verve's lead program, VERVE-102, targets PCSK9...
Sarepta's Elevidys Gene Therapy Halted After Second Acute Liver Failure Death
Sarepta Therapeutics halted shipments of its DMD gene therapy Elevidys to non-ambulatory patients following a second fatal case of acute liver failure. Both deaths occurred in adolescent boys with...
Supernus Pharmaceuticals Acquires Sage Therapeutics for Up to $795 Million
Supernus Pharmaceuticals agreed to acquire Sage Therapeutics at an initial valuation of approximately $561 million, with additional contingent payments potentially increasing the deal value to...